EFFECT OF GHRELIN ANTAGONIST ON FOOD AND WATER INTAKE IN OBESE AND TYPE 2 DIABETIC MICE

Authors

  • Lubna Siddique Department of Physiology, Margalla Institute of Health Sciences, Rawalpindi
  • Madiha Imran Foundation University Medical College, Islamabad

DOI:

https://doi.org/10.69656/pjp.v13i1.265

Keywords:

Ghrelin, Ghrelin antagonist, Obesity, Diabetes, T2DM

Abstract

Background: Ghrelin is the most common orexigenic hormone which acts as starvation signal by acting on hypothalamic neurons. It acts as adipogenic agent. Increased food intake caused by high levels of ghrelin causes increase fat mass. We investigated the possible beneficial role of ghrelin antagonist on food and water intake in obese and type 2 diabetic mice. Methods: This study was carried out at Department of Physiology, Army Medical College, Rawalpindi in collaboration with National Institute of Health, Islamabad, from Jan to Jun 2013. A total of 50 healthy male BALB/c mice were divided into 5 groups. Group I served as control, groups II and III were obese, and group IV and V were diabetic. Group II, III, IV and V were fed high-fat diet for 4 weeks. Group IV and V were given intraperitoneal (IP) injection of streptozotocin to induce type 2 diabetes mellitus. Ghrelin antagonist was injected IP to Group III and V for 6 days. Food and water intake were measured daily. Body weights were measured twice a week and at the end of experiment. Terminal intracardiac blood extraction was done and samples were analyzed for fasting plasma glucose levels. Results: Food intake decreased significantly in group III (obese with Ghrelin antagonist) and group V (diabetic with Ghrelin antagonist) as compared to controls after injection of ghrelin antagonist. Conclusion: Ghrelin antagonist decreases the food and water intake significantly in obese and type 2 diabetic mice.

Pak J Physiol 2017;13(1):39–42

Downloads

Download data is not yet available.

References

1. Field AE, Coakley EH, Must A, Spadano JL, Laird N, Dietz WH, et al. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Inter Med 2001;161:1581–6.
2. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA 1999;282(16):1523–9.
3. Hady HR, Dadan J, Golaszewski P, Safiejko K. Impact of laparoscopic sleeve gastrectomy on body mass index, ghrelin, insulin and lipid levels in 100 obese patients. Wideochir Inne Tech Maloinwazyjne 2012;7:251–9.
4. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539–53.
5. Czech A, Taton J, Piatkiewicz P. Cellular glucose transport disturbances in the pathogenesis and therapy of type 2 diabetes mellitus. Endokrynologia Polska. 2010;61(3):292–302.
6. Rubino F. Bariatric surgery: effects on glucose homeostasis. Curr Opin Clin Nutr Metab Care. 2006;9:497–507.
7. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999;402:656–60.
8. Date Y, Nakazato M, Hashiguchi S, Dezaki K, Mondal MS, Hosoda H, et al. Ghrelin is present in pancreatic alpha-cells of humans and rats and stimulates insulin secretion. Diabetes 2002;51(1):124–9.
9. Asakawa A, Inui A, Kaga T, Katsuura G, Fujimiya M, Fujino MA, et al. Antagonism of ghrelin receptor reduces food intake and body weight gain in mice. Gut 2003;52:947–52.
10. Dezaki K, Kakei M, Yada T. Ghrelin uses Galphai2 and activates voltage-dependent K+ channels to attenuate glucose-induced Ca2+ signaling and insulin release in islet beta-cells: novel signal transduction of ghrelin. Diabetes 2007;56:2319–27.
11. Reusser F. Mode of action of streptozotocin. J Bacteriol 1971;105(2):580–8.
12. Chin CY, Monack DM, Nathan S. Delayed activation of host innate immune pathways in streptozotocin-induced diabetic hosts leads to more severe disease during infection with Burkholderia pseudomallei. Immunology. 2012;135:312–32.
13. Xu G, Wang Z, Li Y, Li Z, Tang H, Zhao J, et al. Ghrelin contributes to derangements of glucose metabolism induced by rapamycin in mice. Diabetologia 2012;55:1813–23.
14. Dupouy VM, Ferre PJ, Uro-Coste E, Lefebvre HP. Time course of COX-1 and COX-2 expression during ischemia-reperfusion in rat skeletal muscle. J Appl Physiol 2006;100(1):233–9.
15. Dong J, Peeters TL, De Smet B, Moechars D, Delporte C, Vanden Berghe P, et al. Role of endogenous ghrelin in the hyperphagia of mice with streptozotocin-induced diabetes. Endocrinology. 2006;147:2634–42.
16. Esler WP, Rudolph J, Claus TH, Tang W, Barucci N, Brown SE, et al. Small-molecule ghrelin receptor antagonists improve glucose tolerance, suppress appetite, and promote weight loss. Endocrinology. 2007;148:5175–85.
17. Gomez JL, Ryabinin AE. The effects of ghrelin antagonists [D-Lys(3) ]-GHRP-6 or JMV2959 on ethanol, water, and food intake in C57BL/6J mice. Alcohol Clin Exp Res. 2014;38:2436–44.
18. Mietlicki EG, Nowak EL, Daniels D. The effect of ghrelin on water intake during dipsogenic conditions. Physiol Behav. 2009;96(1):37–43.

Downloads

Published

31-03-2017

How to Cite

1.
Siddique L, Imran M. EFFECT OF GHRELIN ANTAGONIST ON FOOD AND WATER INTAKE IN OBESE AND TYPE 2 DIABETIC MICE. Pak J Phsyiol [Internet]. 2017 Mar. 31 [cited 2024 Dec. 27];13(1):39-42. Available from: https://pjp.pps.org.pk/index.php/PJP/article/view/265

Issue

Vol. 13 No. 1 (2017): Pakistan Journal of Physiology

Section

Original Article

License

Pakistan Journal of Physiology, Pak J Physiol, PJP is FREE for research and academic purposes. It can be freely downloaded and stored, printed, presented, projected, cited and quoted with full reference of, and acknowledgement to the author(s) and the PJP. The contents are published with an international CC-BY-ND-4.0 License.